C. Coens

M. Piccart, I. Vergote, P. Willemse, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

D. Schadendorf, P. Ascierto, A. Bottomley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy

P. Bossuyt, G. Kenter, I. Vergote, 2018, International Journal of Gynecologic Cancer.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

M. Parmar, M. Parmar, G. Jayson, 2018, The Lancet. Oncology.

This is a repository copy of A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line

Robin L. Jones, I. Ray-Coquard, B. Seddon, 2020 .

Minimally important differences for interpreting the EORTC QLQ-C30 in advanced 1 colorectal cancer patients treated with chemotherapy.

M. Groenvold, M. Sprangers, A. Bottomley, 2021 .

Reply to B. Freidlin et al.

A. Jimeno, I. Vergote, C. Coens, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

A. Bottomley, J. Bernier, É. Remenár, 2010, British Journal of Cancer.

Interpreting EORTC QLQ-C30 scores as minimally importantly different (MID) for patients with malignant melanoma

M. Groenvold, M. Sprangers, A. Bottomley, 2020 .

K. Van Steen, M. Piccart, M. Sprangers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971.

S. Stewart, J. Bernier, É. Remenár, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients

R. Stupp, M. J. van den Bent, M. Weller, 2020, Neuro-oncology practice.

Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.

G. Giaccone, A. Bottomley, L. Thiberville, 2008, European journal of cancer.

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

L. Minasian, E. Basch, C. Cleeland, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA)

G. Kenter, I. Vergote, F. Amant, 2008 .

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

R. Stupp, M. J. van den Bent, M. Taphoorn, 2021, Neuro-oncology.

EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials

E. Berns, A. Jimeno, D. Katsaros, 2012 .

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.

G. Giaccone, A. Bottomley, E. Smit, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2012, The Lancet.

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

M. Franchi, I. Vergote, C. Coens, 2003, Journal of the National Cancer Institute.

A. Bottomley, P. Therasse, J. Blazeby, 2005, European journal of cancer.

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Murielle Mauer, Corneel Coens, Andrew Bottomley, 2009, The Lancet. Oncology.

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Michael Koller, Corneel Coens, Andrew Bottomley, 2020, The Lancet. Oncology.

M. Hassel, K. Hoang-Xuan, R. Stupp, 2016, The Lancet. Oncology.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

M. J. van den Bent, M. Weller, M. Taphoorn, 2018, The Lancet Oncology.

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

P. V. van Diest, E. Berns, M. Vijver, 2006, European journal of cancer.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

L. Collette, M. Piccart, M. Taphoorn, 2016, The Lancet. Oncology.

An international phase 3 trial in head and neck cancer: Quality of life and symptom results

I. Barillot, A. Bottomley, C. Coens, 2014, Cancer.

Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Corneel Coens, Andrew Bottomley, John Maringwa, 2011, Journal of the National Cancer Institute.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

E. Berns, A. Jimeno, D. Lambrechts, 2015, Targeted Oncology.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup

A. Jimeno, D. Katsaros, I. Vergote, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

G. Kenter, I. Vergote, F. Amant, 2010, The New England journal of medicine.

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Corneel Coens, Alan Lamont, Gordon C Jayson, 2010, The Lancet.

FIRST RESULTS OF A RANDOMISED TRIAL COMPARING RADIOTHERAPY VERSUS- OBSERVATION POST OPERATIVELY IN PATIENTS WITH UTERINE SARCOMAS. AN EORTC-GCG STUDY

A. Poveda, I. Vergote, C. Mangioni, 2003, International Journal of Gynecologic Cancer.

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

M. Franchi, I. Vergote, A. Poveda, 2008, European journal of cancer.

Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

H. Bonnefoi, I. Vergote, C. Coens, 2003, European journal of cancer.

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.

M. Groenvold, M. Sprangers, A. Bottomley, 2020, Gynecologic oncology.

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

Robin L. Jones, P. Casali, I. Ray-Coquard, 2020, International Journal of Gynecological Cancer.

Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.

A. Bottomley, J. V. van Meerbeeck, C. Legrand, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

M. Groenvold, A. Bottomley, M. King, 2021, BMC Cancer.

Quality of life of long‐term childhood acute lymphoblastic leukemia survivors: Comparison with healthy controls

P. Rohrlich, A. Darlington, P. Missotten, 2022, Psycho-oncology.

Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.

M. Namer, P. Zola, C. Coens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

D. Osoba, M. Taphoorn, C. Gotay, 2014, Cancer.

An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32).

S. Schraub, N. Aaronson, A. Bottomley, 2005, European journal of cancer.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

L. Collette, M. Piccart, J. Reijneveld, 2018, The Lancet. Oncology.

Statistical methodology of phase III cancer clinical trials: advances and future perspectives.

M. van Glabbeke, L. Collette, T. Gorlia, 2002, European journal of cancer.

Predicting survival using health related quality of life scores in glioblastoma cancers: Findings from an international phase III randomised controlled trial

D. Osoba, R. Stupp, W. Mason, 2005 .

R. Stupp, M. Sprangers, A. Bottomley, 2014, The Lancet. Oncology.

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.

M. J. van den Bent, M. Weller, T. Gorlia, 2021, European journal of cancer.

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

M. J. van den Bent, M. Weller, T. Gorlia, 2019, Neuro-oncology.

Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.

R. Stupp, M. Taphoorn, J. Reijneveld, 2019, International journal of radiation oncology, biology, physics.

Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data

D. Osoba, M. Taphoorn, C. Gotay, 2011, Expert review of pharmacoeconomics & outcomes research.

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.

J. Seoane, I. Vergote, R. Verheijen, 2011, European journal of cancer.

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Maria Werner-Wasik, Tito R Mendoza, Corneel Coens, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

M. Groenvold, M. Sprangers, A. Bottomley, 2018, European journal of cancer.

Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.

D. Katsaros, G. Kenter, I. Vergote, 2019, Journal of Clinical Oncology.

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients

R. Stupp, M. J. van den Bent, M. Taphoorn, 2021, Neuro-oncology.

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.

D. Osoba, R. Stupp, M. J. van den Bent, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors

J. Briones, A. Bottomley, M. André, 2021, European journal of haematology.

Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol

M. Groenvold, M. Sprangers, A. Bottomley, 2018, BMJ Open.

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.

R. Stupp, M. J. van den Bent, M. Weller, 2019, European journal of cancer.

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.

A. Bottomley, F. Lévi, Y. Humblet, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation

C. Gotay, A. Bottomley, M. Mauer, 2008, Expert review of pharmacoeconomics & outcomes research.

Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

M. J. van den Bent, M. Taphoorn, A. Brandes, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

D. Osoba, R. Mirimanoff, R. Stupp, 2007, British Journal of Cancer.

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients.

D. Osoba, R. Mirimanoff, R. Stupp, 2010, European journal of cancer.

Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials

Corneel Coens, Andrew Bottomley, Dongsheng Tu, 2018, Cancer.

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

M. Piccart, A. Bottomley, T. Čufer, 2004, European journal of cancer.

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.

A. Bottomley, M. Koller, T. Conroy, 2004, European journal of cancer.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

L. Collette, M. Bolla, J. Bosset, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients

M. Taphoorn, J. Reijneveld, J. Heimans, 2016, Quality of Life Research.

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?

R. Stupp, M. J. van den Bent, M. Weller, 2019, Neuro-oncology.

The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.

M. Taphoorn, C. Gotay, B. Reeve, 2016, Journal of the National Cancer Institute.

Determinants of patient satisfaction in oncology settings from European and Asian countries: preliminary results based on the EORTC IN-PATSAT32 questionnaire.

S. Schraub, N. Aaronson, A. Bottomley, 2007, European journal of cancer.

Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer

M. Groenvold, M. Sprangers, A. Bottomley, 2019, JNCI cancer spectrum.

4218 Determining the minimal clinically important difference for health related quality of life scores from the EORTC QLQ-C30 in lung cancer patients: an analysis of pooled data

C. Gotay, A. Bottomley, C. Quinten, 2009 .

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

D. Osoba, M. Taphoorn, C. Gotay, 2011, Supportive Care in Cancer.

Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.

M. Groenvold, M. Sprangers, A. Bottomley, 2022, Lung cancer.

Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy

M. Groenvold, M. Sprangers, A. Bottomley, 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer

V. Grégoire, M. Groenvold, M. Sprangers, 2020, Head & neck.

The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.

M. Taphoorn, B. Reeve, K. Bjordal, 2015, European journal of cancer.

Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century

L. Collette, T. Gorlia, S. Litière, 2012 .

A. Bottomley, C. Quinten, J. V. van Meerbeeck, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Bottomley, H. Wildiers, G. Curigliano, 2022, Journal of geriatric oncology.

Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative.

D. Osoba, M. Taphoorn, C. Gotay, 2009, European journal of cancer care.

Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patients.

M. Franchi, I. Vergote, C. Coens, 2007, European journal of cancer.

Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program

H. Gómez, A. Wolff, F. Cardoso, 2018 .

A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials.

A. Bottomley, J. Hamel, C. Coens, 2017, European journal of cancer.

Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative.

Susan M. Chang, P. Brown, M. Gilbert, 2021, Neuro-oncology practice.

Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.

M. Taphoorn, J. Reijneveld, M. Groenvold, 2023, European journal of cancer.

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group).

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Measuring the Quality of Life of Patients with Cancer

A. Bottomley, C. Coens, D. Ediebah, 2014 .

Proceedings of Patient Reported Outcome Measures (PROMs) Conference Birmingham 2018

Kathy, Mogens, Collette, 2018, Journal of Patient-Reported Outcomes.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

L. Collette, M. Piccart, M. Taphoorn, 2018, Clinical trials.

The effects of age on health-related quality of life in cancer populations: a pooled analysis of randomized controlled trials using the EORTC QLQ- C30 involving 6,106 cancer patients

K. Bjordal, C. Quinten, J. Ringash, 2017 .

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial

E. Rutgers, R. Mansel, C. V. D. van de Velde, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

G. Giaccone, L. Thiberville, E. Felip, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making.

D. Osoba, C. Gotay, A. Bottomley, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

M. Piccart, R. Mansel, A. Bottomley, 2019, European journal of cancer.

Lymph Node Sampling and Taking of Blind Biopsies Are Important Elements of the Surgical Staging of Early Ovarian Cancer

I. Vergote, C. Coens, P. Timmers, 2010, International Journal of Gynecologic Cancer.

Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

J. Pichler, M. Weller, C. Marosi, 2021, Neuro-oncology.

Sociodemographic and Medical Determinants of Quality of Life in Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled in EORTC CLG Studies

P. Rohrlich, A. Darlington, J. van der Werff Ten Bosch, 2021, Cancers.

Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC).

D. Lacombe, J. Machiels, Yan Liu, 2017, European journal of cancer.

Prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence: a report from the EORTC 26091 TAVAREC trial.

M. J. van den Bent, M. Taphoorn, T. Gorlia, 2022, Clinical Cancer Research.

M. J. van den Bent, M. Taphoorn, J. Reijneveld, 2023, European journal of cancer.

INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY

M. Piccart, I. Vergote, P. Willemse, 2003, International Journal of Gynecologic Cancer.

Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.

Susan M. Chang, M. Gilbert, P. Wen, 2020, The Lancet. Oncology.

Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group.

J. Reijneveld, B. Reeve, C. Cleeland, 2023, The Lancet. Oncology.

The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG

D. Osoba, R. Mirimanoff, R. Stupp, 2008 .

Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).

A. Wolff, S. Giordano, K. Ruddy, 2023, The oncologist.

Prognostic value of Ic substages in invasive epithelial ovarian carcinoma

A. Zwinderman, J. Trimbos, I. Vergote, 2014 .

A systematic review examining factors influencing health related quality of life among melanoma cancer survivors.

Corneel Coens, Andrew Bottomley, Francesca Martinelli, 2016, European journal of cancer.

Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial.

M. Piccart, A. Bottomley, P. Therasse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Missing data: Discussion points from the PSI missing data expert group

Brian Sullivan, James Carpenter, Corneel Coens, 2010, Pharmaceutical statistics.

Quality of life of long-term childhood acute lymphoblastic leukemia survivors European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLG) and Children's Leukemia

P. Rohrlich, A. Darlington, P. Missotten, 2022 .

A population-based approach to compare patient-reported outcomes of long-term Hodgkin’s lymphoma survivors according to trial participation: a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Re

J. Bogaerts, L. V. van de Poll-Franse, C. Coens, 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A. Bottomley, C. Quinten, J. V. van Meerbeeck, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

J. Bogaerts, G. Tienhoven, G. Nieuwenhuijzen, 2014, The Lancet. Oncology.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

G. Kenter, M. Nankivell, S. Kehoe, 2018, The Lancet. Oncology.

University of Birmingham Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

L. Collette, M. Piccart, M. Taphoorn, 2018 .

P. Ascierto, R. Dummer, J. Wolchok, 2017, The Lancet. Oncology.

D. Schadendorf, R. Dummer, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of health-related quality of life assessment in cancer clinical trials

P. Fargeot, C. Coens, F. Efficace, 2007 .

PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE

A. Bottomley, M. Mauer, C. Coens, 2008 .

Statistical methodology is crucial in prognostic factor analysis of health-related quality of life

A. Bottomley, M. Mauer, C. Coens, 2008, Quality of Life Research.

An international phase 3 trial in head and neck cancer: Quality of life and symptom results

I. Barillot, A. Bottomley, C. Coens, 2014, Cancer.

A. Jimeno, D. Katsaros, I. Ray-Coquard, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

D. Katsaros, I. Vergote, F. Landoni, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of Oncology.